Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFINE: Evaluating Therapies for COVID-19
NCT04473053Phase 2Completed
- Sponsor
- University of Edinburgh
- Start
- Jul 2020
- Primary completion
- Apr 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Nafabelltan, GB0139, allogeneic SARS-CoV-2 virus-specific T-cells in coronavirus disease 2019 (COVID-19), sponsored by University of Edinburgh. Started Jul 2020; status: completed.
02
Drugs
NafabelltanGB0139allogeneic SARS-CoV-2 virus-specific T-cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04473053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04473053.